Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Market Reports
NEW
 Top 50 Non-Healthcare Market Reports
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Denosumab Global Market Report 2025
Request Sample Buy Now
Global Denosumab Market Report 2025

Report Price : $4490.00

Pages : 175

Format : PDF

Published : January 2025

Delivery Time : 2-3 Business Days

Purchase This Report
Purchase This Report

Denosumab Global Market Report 2025

By Drug Classification (Prolia, Xgeva, Others), By Type (60 mg, 120 mg), By End-Users (Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Denosumab Market Overview

• Denosumab market size has reached to $3.27 billion in 2024

• Expected to grow to $5.48 billion in 2029 at a compound annual growth rate (CAGR) of 10.6%

• Growth Driver: Denosumab Market Growth Fueled By Rising Osteoporosis Prevalence

• Market Trend: Emphasis On First-Line Denosumab Treatments For Osteoporosis

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Denosumab Market?

Denosumab is a monoclonal antibody used to treat bone-related conditions, particularly osteoporosis and bone metastases. It works by inhibiting osteoclast formation, decreasing bone resorption, increasing bone mineral density, and reducing the risk of fracture.

The main types of denosumab drug classifications include Prolia, Xgeva, and others. Prolia refers to a prescription medicine utilized to treat osteoporosis in postmenopausal women who are at high risk for fracture or cannot use another osteoporosis medication. These are available in 60 mg and 120 mg, which are used by various end-users, such as hospitals, home care, specialty clinics, and ambulatory surgical centers.

Denosumab Market Size and growth rate 2025 to 2029: Graph

What Is The Denosumab Market Size 2025 And Growth Rate?

The denosumab market size has grown rapidly in recent years. It will grow from $3.27 billion in 2024 to $3.67 billion in 2025 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to clinical trials and research advancements, FDA approvals and regulatory milestones, growing awareness of bone health, strategic partnerships and marketing initiatives.

What Is The Denosumab Market Growth Forecast?

The denosumab market size is expected to see rapid growth in the next few years. It will grow to $5.48 billion in 2029 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to rising incidence of bone metastases, advancements in cancer therapies, osteoporosis prevalence, increased awareness of osteoporosis, regulatory approvals for new indications. Major trends in the forecast period include strategic collaborations and partnerships, integration with digital health solutions, expanded indications and clinical applications, advancements in biosimilar development.

The forecast of 10.6% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. endocrinology practices by inflating prices of denosumab biologics manufactured in Belgium and Denmark, resulting in limited osteoporosis treatment options and higher bone health management expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How Is The Denosumab Market Segmented?

1) By Drug Classification: Prolia, Xgeva, Others

2) By Type: 60 mg, 120 mg

3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers

What Is Driving The Denosumab Market? Denosumab Market Growth Fueled By Rising Osteoporosis Prevalence

The increasing prevalence of osteoporosis is expected to propel the growth of the denosumab market going forward. Osteoporosis is a medical condition where the bones become weak, resulting in lower bone density and a higher risk of fractures. Denosumab is used to treat osteoporosis by stopping bone resorption through the targeting of the RANK ligand. For instance, in September 2023, according to the National Center for Biotechnology Information, a US-based government agency, data from the Canadian Longitudinal Study on Aging shows that the prevalence of physician-diagnosed osteoporosis was 12.7% and DXA-confirmed osteoporosis was 5.9% in females among community-dwelling older adults. Additionally, Buttros and colleagues conducted a cross-sectional study that revealed a 24.6% prevalence of osteoporosis in postmenopausal women aged 40 to 75, diagnosed using bone mineral density (BMD) measurements. Therefore, the increasing prevalence of osteoporosis is driving the growth of the denosumab industry.

Who Are The Major Players In The Global Denosumab Market?

Major companies operating in the denosumab market report are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Mylan N.V., Sandoz International GmbH, Daiichi Sankyo Company Limited, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Celltrion Inc., Amneal Pharmaceuticals Inc, Cadila Healthcare Limited, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Jubilant Life Sciences Limited, Ajanta Pharma Limited

What Are The Key Trends Of The Global Denosumab Market? Emphasis On First-Line Denosumab Treatments For Osteoporosis

Major companies operating in the denosumab market are increasing their focus on introducing innovative solutions, such as first-line treatments for osteoporosis, to gain a competitive edge in the market. First-line treatment for osteoporosis refers to the initial or primary therapeutic approach recommended by healthcare professionals when managing individuals diagnosed with osteoporosis. For instance, in November 2022, Boan Biotech, a China-based biotechnology company, received approval from China's National Medical Products Administration (NMPA) for its denosumab biosimilar, Boyoubei, making IT the first Chinese company to develop a denosumab injection. It is also being developed for markets outside of China, including Europe and the United States, with plans for global marketing. The drug has been recommended as a first-line treatment for osteoporosis in various treatment guidelines. The medication has the potential to dramatically lower the risk of hip, non-vertebral, and vertebral fractures in this patient population. Additionally, Boyoubei is the first biosimilar to Prolia (the originator of denosumab) approved for marketing in the world.

Need data on a specific region in this market?
Request Customisation

What Are Latest Mergers And Acquisitions In The Denosumab Market? Organon Partners With Henlius To Commercialize Investigational Biosimilars

In June 2022, Organon, a US-based pharmaceutical company, partnered with Henlius to commercialize Henlius for an undisclosed amount. The partnership allows Organon to license the commercialization rights for biosimilar candidates referencing Perjeta (Pertuzumab, HLX11) and Prolia or Xgeva (Denosumab). This collaboration is in line with Organon's expertise in biosimilar commercialization and its commitment to offering high-quality and affordable biologic medicines for patients worldwide, particularly in the field of women's health. Henlius is a China-based biopharmaceutical company that develops Denosumab biosimilars, such as HLX14

What Is The Regional Outlook For The Global Denosumab Market?

North America was the largest region in the denosumab market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Denosumab Market?

The denosumab market consists of sales of calcium supplements and vitamin D supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Denosumab Industry?

The denosumab market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the denosumab industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Denosumab Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $3.67 billion
Revenue Forecast In 2034 $5.48 billion
Growth Rate CAGR of 10.6% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Drug Classification: Prolia, Xgeva, Others
2) By Type: 60 mg, 120 mg
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Mylan N.V., Sandoz International GmbH, Daiichi Sankyo Company Limited, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Celltrion Inc., Amneal Pharmaceuticals Inc, Cadila Healthcare Limited, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Jubilant Life Sciences Limited, Ajanta Pharma Limited
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Denosumab Market Characteristics

3. Denosumab Market Trends And Strategies

4. Denosumab Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Denosumab Growth Analysis And Strategic Analysis Framework

5.1. Global Denosumab PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Denosumab Market Growth Rate Analysis

5.4. Global Denosumab Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Denosumab Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Denosumab Total Addressable Market (TAM)

6. Denosumab Market Segmentation

6.1. Global Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Prolia

Xgeva

Others

6.2. Global Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

60 mg

120 mg

6.3. Global Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Homecare

Specialty Clinics

Ambulatory Surgical Centers

7. Denosumab Market Regional And Country Analysis

7.1. Global Denosumab Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Denosumab Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Denosumab Market

8.1. Asia-Pacific Denosumab Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Denosumab Market

9.1. China Denosumab Market Overview

9.2. China Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Denosumab Market

10.1. India Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Denosumab Market

11.1. Japan Denosumab Market Overview

11.2. Japan Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Denosumab Market

12.1. Australia Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Denosumab Market

13.1. Indonesia Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Denosumab Market

14.1. South Korea Denosumab Market Overview

14.2. South Korea Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Denosumab Market

15.1. Western Europe Denosumab Market Overview

15.2. Western Europe Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Denosumab Market

16.1. UK Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Denosumab Market

17.1. Germany Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Denosumab Market

18.1. France Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Denosumab Market

19.1. Italy Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Denosumab Market

20.1. Spain Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Denosumab Market

21.1. Eastern Europe Denosumab Market Overview

21.2. Eastern Europe Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Denosumab Market

22.1. Russia Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Denosumab Market

23.1. North America Denosumab Market Overview

23.2. North America Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Denosumab Market

24.1. USA Denosumab Market Overview

24.2. USA Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Denosumab Market

25.1. Canada Denosumab Market Overview

25.2. Canada Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Denosumab Market

26.1. South America Denosumab Market Overview

26.2. South America Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Denosumab Market

27.1. Brazil Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Denosumab Market

28.1. Middle East Denosumab Market Overview

28.2. Middle East Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Denosumab Market

29.1. Africa Denosumab Market Overview

29.2. Africa Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Denosumab Market Competitive Landscape And Company Profiles

30.1. Denosumab Market Competitive Landscape

30.2. Denosumab Market Company Profiles

30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Denosumab Market Other Major And Innovative Companies

31.1. Eli Lilly and Company

31.2. Amgen Inc.

31.3. Asahi Kasei Corporation

31.4. Teva Pharmaceutical Industries Ltd.

31.5. Astellas Pharma Inc.

31.6. Daiichi Sankyo Company, Limited

31.7. Mylan N.V.

31.8. Sandoz International GmbH

31.9. Daiichi Sankyo Company Limited

31.10. Aurobindo Pharma Limited

31.11. Cipla Limited

31.12. Dr. Reddy's Laboratories Ltd.

31.13. Hikma Pharmaceuticals PLC

31.14. Celltrion Inc.

31.15. Amneal Pharmaceuticals Inc

32. Global Denosumab Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Denosumab Market

34. Recent Developments In The Denosumab Market

35. Denosumab Market High Potential Countries, Segments and Strategies

35.1 Denosumab Market In 2029 - Countries Offering Most New Opportunities

35.2 Denosumab Market In 2029 - Segments Offering Most New Opportunities

35.3 Denosumab Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Denosumab Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Denosumab Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Asia-Pacific, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Asia-Pacific, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Asia-Pacific, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: China, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: China, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: China, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: India, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: India, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: India, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: Japan, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: Japan, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: Japan, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: Australia, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: Australia, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Australia, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Indonesia, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Indonesia, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Indonesia, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: South Korea, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: South Korea, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: South Korea, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Western Europe, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Western Europe, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: Western Europe, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: UK, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: UK, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: UK, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Germany, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: Germany, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: Germany, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: France, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: France, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: France, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Italy, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: Italy, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: Italy, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: Spain, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Spain, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Spain, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Eastern Europe, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Eastern Europe, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Eastern Europe, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Russia, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Russia, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Russia, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: North America, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: North America, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: North America, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: USA, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: USA, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: USA, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: Canada, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: Canada, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: Canada, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: South America, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: South America, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: South America, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Brazil, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: Brazil, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: Brazil, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: Middle East, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Middle East, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Middle East, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Africa, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Africa, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Africa, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Johnson & Johnson Financial Performance
  • Table 75: F. Hoffmann-La Roche Ltd. Financial Performance
  • Table 76: Novartis International AG Financial Performance
  • Table 77: Sanofi SA Financial Performance
  • Table 78: GlaxoSmithKline plc Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Denosumab Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Denosumab Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Asia-Pacific, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Asia-Pacific, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Asia-Pacific, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: China, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: China, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: China, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: India, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: India, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: India, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: Japan, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: Japan, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: Japan, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: Australia, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: Australia, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Australia, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Indonesia, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Indonesia, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Indonesia, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: South Korea, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: South Korea, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: South Korea, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Western Europe, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Western Europe, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: Western Europe, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: UK, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: UK, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: UK, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Germany, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: Germany, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: Germany, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: France, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: France, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: France, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Italy, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: Italy, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: Italy, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: Spain, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Spain, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Spain, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Eastern Europe, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Eastern Europe, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Eastern Europe, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Russia, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Russia, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Russia, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: North America, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: North America, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: North America, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: USA, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: USA, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: USA, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: Canada, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: Canada, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: Canada, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: South America, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: South America, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: South America, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Brazil, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: Brazil, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: Brazil, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: Middle East, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Middle East, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Middle East, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Africa, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Africa, Denosumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Africa, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Johnson & Johnson Financial Performance
  • Figure 75: F. Hoffmann-La Roche Ltd. Financial Performance
  • Figure 76: Novartis International AG Financial Performance
  • Figure 77: Sanofi SA Financial Performance
  • Figure 78: GlaxoSmithKline plc Financial Performance

Key Market Drivers, Trends, and Forecast for the Global Non-Steroidal Anti-inflammatory Drugs Industry

Read More About Key Market Drivers, Trends, and Forecast for the Global Non-Steroidal Anti-inflammatory Drugs Industry

Outlook for Non-Therapeutic Biomolecules Market: Key Developments and Future Strategies to 2029

Read More About Outlook for Non-Therapeutic Biomolecules Market: Key Developments and Future Strategies to 2029

Global Pain Management Drugs Market Forecast to Reach $104.19 Billion by 2029, Driven by 5.6% CAGR

Read More About Global Pain Management Drugs Market Forecast to Reach $104.19 Billion by 2029, Driven by 5.6% CAGR

Pericarditis Industry Poised for Rapid Expansion, Projected to Hit $3.37 Billion by 2029

Read More About Pericarditis Industry Poised for Rapid Expansion, Projected to Hit $3.37 Billion by 2029

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

Read More About A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

Read More About A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

Read More About A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

Uncover TBRC’s strategic outlook on technological trends, regulatory factors, and market growth in transdermal drug delivery systems.

Read More About Uncover TBRC’s strategic outlook on technological trends, regulatory factors, and market growth in transdermal drug delivery systems.

Stress Tests Equipment Global Market Report 2025 – By Product Type (Treadmill Stress Test Systems, Ergometry Equipment, Cardiopulmonary Exercise Testing (CPET) Equipment, Exercise ECG Systems, Echocardiogram, Supplies An...

View Report

Silicon Carbide Power Semiconductor Global Market Report 2025 – By Type (Metal-Oxide Semiconductor Field-Effect Transistors (MOSFETs), Hybrid Modules, Schottky Barrier Diodes (SBDS), Insulated Gate Bipolar Transistors (I...

View Report

Multi-Cloud Management Global Market Report 2025 – By Solution (Security And Risk Management, Training And Consulting, Reporting And Analytics, Cloud Automation, Managed Services, Other Solutions), By Deployment Model (P...

View Report

Reed Switch Device Global Market Report 2025 – By Product Type (Normally Open (A-Type), Normally Closed (B-Type), Changeover (C-Type) ), By Distribution Channel (Direct Sales, Distributor ), By Application (Magnetic Sens...

View Report

Dairy Testing Global Market Report 2025 – By Type (Safety Testing, Quality Testing), By Technology (HPLC-Based, LC-MS/MS-Based, Immunoassay-Based, Other Technologies), By Application (Ice-Creams And Desserts, Infant Food...

View Report

Desiccants Global Market Report 2025 – By Type (Silica Gel, Zeolite, Activated Alumina, Activated Charcoal, Calcium Chloride, Clay, Other Types), By Process (Physical Absorption, Chemical Absorption), By Application (Ele...

View Report

Biomarker Discovery Outsourcing Services Global Market Report 2025 – By Type (Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers, Surrogate Endpoints), By Discovery Phase (Biomarker Identification, Biomarker...

View Report

Malted Barley Global Market Report 2025 – By Type (Basic Malt, Special Mal), By Form (Flakes, Pellets, Granular, Powder, Liquid), By Application (Brewing Industry, Food Industry, Pharmaceutical, Other Applications) – Imp...

View Report

Frequently Asked Questions

Denosumab is a monoclonal antibody used to treat bone-related conditions, particularly osteoporosis and bone metastases. It works by inhibiting osteoclast formation, decreasing bone resorption, increasing bone mineral density, and reducing the risk of fracture. For further insights on this market, request a sample here

The market major growth driver - Denosumab Market Growth Fueled By Rising Osteoporosis Prevalence. For further insights on this market, request a sample here

The denosumab market size has grown rapidly in recent years. It will grow from $3.27 billion in 2024 to $3.67 billion in 2025 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to clinical trials and research advancements, FDA approvals and regulatory milestones, growing awareness of bone health, strategic partnerships and marketing initiatives. The denosumab market size is expected to see rapid growth in the next few years. It will grow to " $5.48 billion in 2029 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to rising incidence of bone metastases, advancements in cancer therapies, osteoporosis prevalence, increased awareness of osteoporosis, regulatory approvals for new indications. Major trends in the forecast period include strategic collaborations and partnerships, integration with digital health solutions, expanded indications and clinical applications, advancements in biosimilar development. For further insights on this market, request a sample here

The denosumab market covered in this report is segmented –
1) By Drug Classification: Prolia, Xgeva, Others
2) By Type: 60 mg, 120 mg
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers For further insights on this market, request a sample here

North America was the largest region in the denosumab market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Major companies operating in the denosumab market report are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Mylan N.V., Sandoz International GmbH, Daiichi Sankyo Company Limited, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Celltrion Inc., Amneal Pharmaceuticals Inc, Cadila Healthcare Limited, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Jubilant Life Sciences Limited, Ajanta Pharma Limited. For further insights on this market, request a sample here.

Major trends in this market include Emphasis On First-Line Denosumab Treatments For Osteoporosis. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Denosumab Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top WhatsApp icon